Anti-Hypertensive Drugs - Tunisia

Tunisia

The revenue in Tunisia's Anti-Hypertensive Drugs market is forecasted to reach US$5.04m in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of -0.68%, leading to a market volume of US$4.87m by 2029.
When compared globally, United States is projected to generate the highest revenue, amounting to US$12,290.00m in 2024.
Tunisia's anti-hypertensive drug market is witnessing a surge in demand due to an aging population and increasing prevalence of hypertension.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for anti-hypertensive drugs in Tunisia has been on the rise in recent years.

Customer preferences: The Tunisian population has become increasingly health-conscious, leading to a higher demand for anti-hypertensive drugs. Additionally, the aging population has contributed to the growth of the market as hypertension is more prevalent among older individuals.

Trends in the market: The market for anti-hypertensive drugs in Tunisia is expected to continue growing due to the increasing prevalence of hypertension and the government's efforts to improve healthcare access. The market is also witnessing a shift towards generic drugs as they are more affordable than brand-name drugs.

Local special circumstances: Tunisia has a universal healthcare system, which means that the government provides healthcare services to all citizens. This has contributed to the growth of the anti-hypertensive drugs market as more people have access to healthcare and can afford to buy medication.

Underlying macroeconomic factors: Tunisia's economy has been growing steadily, which has led to an increase in disposable income. This has allowed more people to afford medication, including anti-hypertensive drugs. Additionally, the government's efforts to improve healthcare access have also contributed to the growth of the market. However, the political instability in the country has had a negative impact on the economy, which could potentially affect the growth of the anti-hypertensive drugs market in the future.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.